ITUS - ITUS Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.64
+0.03 (+0.65%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.61
Open4.61
Bid0.00 x 800
Ask0.00 x 900
Day's Range4.60 - 4.76
52 Week Range2.27 - 6.43
Volume68,925
Avg. Volume152,037
Market Cap86.75M
Beta (3Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-0.62
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.12
Trade prices are not sourced from all markets
  • ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
    PR Newswire2 months ago

    ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX

    SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (ITUS), a biotechnology company focused on using the body's immune system to fight cancer, today announced that on October 1, 2018, the Company will officially change its name to Anixa Biosciences, Inc.  Effective at the start of trading on October 1, 2018, the Company's shares will trade on the NASDAQ Capital Market under the new name, and the new stock symbol will be "ANIX."  The Company's website will be accessible at www.anixa.com.

  • GuruFocus.com2 months ago

    Weekly CFO Buys Highlight

    Insiders invest in ITUS, Energy Transfer Partners and PolarityTE

  • Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy
    PR Newswire2 months ago

    Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy

    SAN JOSE, Calif., Sept. 5, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) and its research partner, Moffitt Cancer Center, today announced that a pre-IND meeting with the US FDA has been scheduled on Tuesday, October 16, 2018.  The meeting is to discuss numerous aspects of the planned clinical trial of their CAR-T therapy for ovarian cancer. Dr. Amit Kumar, CEO of ITUS stated, "We are pleased to be meeting with the FDA this fall, as anticipated.  We have submitted pre-clinical data, as well as a series of questions, to the FDA.  Coming out of this meeting, our goal is to have a good understanding of the design for the clinical trial in our Investigational New Drug (IND) application.

  • ITUS Corporation to Present at Next Generation Dx Summit
    PR Newswire3 months ago

    ITUS Corporation to Present at Next Generation Dx Summit

    SAN JOSE, Calif., Aug. 17, 2018  /PRNewswire/ -- ITUS Corporation (ITUS) today announced that CEO, Dr. Amit Kumar, will be presenting at the Next Generation Dx Summit in Washington, D.C., being held on August 20th-24th.  Dr. Kumar's presentation, "Liquid Biopsy based on Flow Cytometry and Artificial Intelligence to Detect the Existence of a Solid Tumor," is scheduled at 2:50 PM EDT, Wednesday, August 22nd.  Dr. Kumar will discuss ITUS's latest data on its Cchek™ diagnostic development, including studies on breast cancer and prostate cancer, as well as data from the collaborative study with Memorial Sloan Kettering and Serametrix.

  • Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T Therapy
    PR Newswire4 months ago

    Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T Therapy

    This meeting, known as a pre-IND meeting, is designed to enable drug developers and the FDA to evaluate a drug's pre-clinical data and its proposed development path in anticipation of filing an Investigational New Drug (IND) application.  ITUS and Moffitt have previously stated that this program is ahead of schedule.  Assuming the FDA does not require additional animal studies, ITUS and Moffitt hope to file the IND application in early 2019 and begin human trials once approved by the FDA.

  • ITUS Corporation Releases Results for Cchek™ Breast Cancer Study
    PR Newswire4 months ago

    ITUS Corporation Releases Results for Cchek™ Breast Cancer Study

    The Cchek™ breast cancer study is focused on early stage cancer, because other methods are poor at accurately identifying stage 1 and 2 malignancies.  The interim results showed sensitivity of 92% and specificity of 87% for stage 1 and 2 cancers.  The interim data utilized blood samples from a total of 144 patients, that included 64 women who had biopsy verified breast cancer, and 80 women with no cancer.  Our AI application was trained with 88 patients and tested with 56.  As later stage patients are added to the study, performance is expected to improve.

  • ITUS Corporation Announces Second Commercial Focus for Cchek™ will be Breast Cancer
    PR Newswire4 months ago

    ITUS Corporation Announces Second Commercial Focus for Cchek™ will be Breast Cancer

    SAN JOSE, Calif. , July 6, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that due to the significance of positive results as well as strong commercial interest, it has selected breast ...

  • ITUS to Ring the NASDAQ Closing Bell on July 5th
    PR Newswire5 months ago

    ITUS to Ring the NASDAQ Closing Bell on July 5th

    ITUS recently announced that the CAR-T therapy for ovarian cancer, being developed in collaboration with The Moffitt Cancer Center, is roughly one year ahead of its original development timeline, and the Company anticipates a pre-IND meeting with the US FDA in the October/November timeframe.  Assuming the FDA does not require significant additional animal studies, the IND application could be filed as soon as Q1 of 2019 with human trials beginning as early as the first half of 2019. The event can be viewed live by visiting https://new.livestream.com/nasdaq/live.

  • ITUS Accelerates Schedule for its CAR T Therapy and Provides Update
    PR Newswire5 months ago

    ITUS Accelerates Schedule for its CAR T Therapy and Provides Update

    SAN JOSE, Calif., June 26, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today provided a status update and accelerated development timeline for its CAR T therapy for Ovarian Cancer, which is in development with Moffitt Cancer Center. ITUS initiated a Cooperative R&D Agreement (CRADA) with Moffitt to advance a proprietary CAR T therapy for ovarian cancer in November 2017.  The study is led by Jose Conejo-Garcia, M.D., Ph.D., Chair of the Department of Immunology at Moffitt.  The aim of this CRADA is to complete the pre-clinical studies necessary for the submission of an IND application to the FDA, seeking approval to test the therapy in human patients.  The previous goal for IND submission was the end of 2019 or early 2020, now it has been accelerated dramatically.

  • ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer
    PR Newswire5 months ago

    ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer

    SAN JOSE, Calif. , June 13, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has chosen prostate cancer as the first commercial focus for its Cchek™, non-invasive liquid biopsy ...

  • ACCESSWIRE5 months ago

    ITUS Corp. (ITUS) Stock: A Disruptive Force In Cancer Diagnostics And Immunotherapy

    CORAL SPRINGS, FL / ACCESSWIRE / June 12, 2018 / Cancer is a devastating illness that affects a large population of patients in the United States. In fact, it is estimated by the National Cancer Institute that in the year 2018 alone, 1.73535 million patients will be diagnosed with cancer and 609,640 Americans will succumb to the ailment. At the helm of innovation in the cancer diagnostics and immunotherapy markets, we find ITUS Corp. (NASDAQ: ITUS).

  • ACCESSWIRE6 months ago

    Complimentary Technical Snapshots on Fiserv and Three More Business Services Stocks

    Research reports have been issued by WallStEquities.com on Fiserv Inc. (NASDAQ: FISV), FleetCor Technologies Inc. (NYSE: FLT), Genpact Ltd (NYSE: G), and ITUS Corp. (NASDAQ: ITUS). Companies in the Business Services sector provide support services, such as office administration, hiring and placing of personnel, security services, travel arrangement, cleaning, and waste disposal, to businesses.

  • Who Really Owns ITUS Corporation (NASDAQ:ITUS)?
    Simply Wall St.7 months ago

    Who Really Owns ITUS Corporation (NASDAQ:ITUS)?

    Today, I will be analyzing ITUS Corporation’s (NASDAQ:ITUS) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects both its short-Read More...

  • ACCESSWIRE7 months ago

    ITUS Corporation to Present at the 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith

    NEW YORK, NY / ACCESSWIRE / May 1, 2018 / ITUS Corporation (NASDAQ: ITUS) announced today that it will be presenting at the 3 rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8 th at ...

  • PR Newswire8 months ago

    ITUS Presentation to Special Meeting of Stockholders

    SAN JOSE, Calif., April 2, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that the presentation given by its Chief Executive Officer, Dr. Amit Kumar, at its Special Meeting of Stockholders on March 29, 2018 has been placed on the Company's website.  It can be viewed at http://ir.ituscorp.com/corporate-presentation.

  • ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study
    PR Newswire8 months ago

    ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study

    SAN JOSE, Calif., March, 27, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that it has completed a prostate cancer study with Serametrix in which data from a previous collaboration between Serametrix and Memorial Sloan Kettering Cancer Center (MSK) was re-evaluated using ITUS technology.

  • ITUS Announces Issuance of Second Key Cancer Detection Technology Patent
    PR Newswire8 months ago

    ITUS Announces Issuance of Second Key Cancer Detection Technology Patent

    SAN JOSE, Calif. , March 26, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat cancer, today announced that the United States Patent ...

  • Where ITUS Corporation (NASDAQ:ITUS) Stands In Earnings Growth Against Its Industry
    Simply Wall St.8 months ago

    Where ITUS Corporation (NASDAQ:ITUS) Stands In Earnings Growth Against Its Industry

    When ITUS Corporation (NASDAQ:ITUS) released its most recent earnings update (31 January 2018), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...

  • ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the American Association of Immunologists (AAI) Meeting
    PR Newswire8 months ago

    ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the American Association of Immunologists (AAI) Meeting

    SAN JOSE, Calif. , March 16, 2018 /PRNewswire/ --   ITUS Corporation (NASDAQ: ITUS), today announced that it will present the latest data from its ongoing early cancer detection study at the annual meeting ...

  • ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting
    PR Newswire8 months ago

    ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting

    SAN JOSE, Calif., March 12, 2018 /PRNewswire/ -- ITUS Corporation (ITUS), today announced that it will present data from its ongoing study utilizing Cchek™, ITUS's artificial intelligence (AI) driven early cancer detection technology.  The presentation will be made at the annual meeting of the American Association of Cancer Research (AACR) in Chicago, Illinois.  The meeting will be held April 14-18, 2018 and will be attended by world leading experts across the field of cancer research.  All abstracts will be viewable by registered attendees beginning March 14, 2018.  To receive a copy of the presentation, please email your request to AACR-2018@ITUScorp.com starting April 19, 2018 and include your name, title, and contact information. The presentation will focus on ITUS' proprietary Cchek™ platform featuring new data and insights into this early cancer detection technology.  Cchek™ combines the immunophenotyping of white blood cells using flow cytometry with a proprietary neural network, a type of artificial intelligence (AI), to detect the presence of solid tumors from a blood sample.  Identifying and measuring circulating myeloid-derived suppressor cells (MDSCs), a group of immunosuppressive white blood cells, is the foundation of this technology.

  • ITUS Corporation to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)
    PR Newswire8 months ago

    ITUS Corporation to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)

    SAN JOSE, Calif. , March 9, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that John Roop , Senior Vice President of Engineering is scheduled to present on Friday March 16, 2018 , ...

  • ITUS Corporation Forms Alliance with Serametrix Corporation
    PR Newswire9 months ago

    ITUS Corporation Forms Alliance with Serametrix Corporation

    SAN JOSE, Calif., March 5, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that ITUS and Serametrix Corporation have signed an agreement to bring the power of Cchek™, ITUS's proprietary, AI-driven liquid biopsy cancer diagnostic technology to Serametrix's substantial expertise in immune monitoring assays.  Serametrix flow cytometry and related data analysis services are already widely used in immunotherapy drug trials.

  • ITUS will Present Artificial Intelligence Powered Early Cancer Detection Technology at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations
    PR Newswire9 months ago

    ITUS will Present Artificial Intelligence Powered Early Cancer Detection Technology at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations

    SAN JOSE, Calif., Feb. 7, 2018 /PRNewswire/ -- ITUS Corporation (ITUS), today announced that its presentation titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," has been accepted for presentation at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations in Montreal, Quebec, Canada.  Myeloid-derived suppressor cells, or MDSCs, are a key group of white blood cells that form the foundation for ITUS' liquid biopsy technology. The presentation will focus on ITUS' proprietary Cchek™ platform which utilizes immuno-profiling via Flow Cytometry and Artificial Intelligence to enable the detection of solid tumors from a blood sample.

  • ACCESSWIRE10 months ago

    Blog Exposure - ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium

    Stock Monitor: Alliance Data Systems Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 31, 2018 / Active-Investors.com has just released a free research report on ITUS Corp. (NASDAQ: ITUS ).If ...

  • Business Wire10 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of ITUS Corporation

    Levi & Korsinsky announces it has commenced an investigation of ITUS Corporation concerning possible breaches of fiduciary duty. To obtain additional information